Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

NEPHRODIAB2 Prospective Randomized Controlled Open-Labelled Trial Comparing Effect of Two Haemoglobin Levels

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2007 by Hospices Civils de Lyon.
Recruitment status was:  Active, not recruiting
Information provided by:
Hospices Civils de Lyon Identifier:
First received: January 18, 2006
Last updated: October 3, 2007
Last verified: October 2007

In type 2 diabetics, progression from chronic kidney disease to end stage renal disease may be slowed down by therapeutic interventions as angiotensin converting enzyme inhibitors use, control of high blood pressure and proteinuria, control of hyperglycaemia, protein intake restriction, smoking cessation.

Correcting anaemia in these patients may prevent impairment of renal function. International guidelines indicate that haemoglobin level has to be of 110 g/L in these patients. We conduct an interventional randomized trial to evaluate the potential benefit of an haemoglobin level of 130 g/L in patients with type 2 diabetes and with a chronic kidney disease defined by a Cockcroft's creatinine clearance of 25 - 60 ml/min.

Condition Intervention
Chronic Kidney Disease
Drug: GROUP A: if necessary, martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 110 to 129 g/L.
Drug: GROUP B: martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 130 to 149 g/L

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Prospective Randomized Controlled Open-Labelled Trial Comparing Effect of Two Haemoglobin Levels (110- 129 g/L and 130 - 149 g/L) on Progression of Chronic Kidney Disease in Patients With Type 2 Diabetes and With Chronic Kidney Disease

Resource links provided by NLM:

Further study details as provided by Hospices Civils de Lyon:

Primary Outcome Measures:
  • Decrease in Cockcroft's creatinine clearance between inclusion and end of two years follow-up period.

Secondary Outcome Measures:
  • Death
  • Angina
  • Stroke
  • Peripheral acute ischemia, vascular angioplasty, surgical vascular bypass, amputation
  • Heart failure
  • Pulmonary embolism
  • Deep venous thrombosis and haemodialysis fistula thrombosis
  • Bacterial infectious disease
  • Renal replacement therapy (dialysis or pre-emptive renal transplantation)
  • Quality of life: SF 36 auto-questionnaire

Estimated Enrollment: 204
Study Start Date: January 2004

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Type 2 diabetes. Age between 18 and 80 years, male or female. Cockcroft's clearance between 25 and 60 ml / min. Haemoglobin level superior to 100 g/L and strictly inferior to 130 g/L

Exclusion Criteria:

Malignancy Solid organ transplant Acute pathology in the two months before inclusion date Myocardial infarction, stroke, pulmonary embolism in the six months before inclusion date Contra-indication to martial treatment or EPO treatment Present inclusion in another clinical study Patient who cannot answer questions of SF36 questionnaire

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00279084

Joëlle Gillet
Lyon, France, 69376
Sponsors and Collaborators
Hospices Civils de Lyon
Principal Investigator: Emmanuel VILLAR, MD Hospices Civils de Lyon
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00279084     History of Changes
Other Study ID Numbers: 2003.315
Study First Received: January 18, 2006
Last Updated: October 3, 2007

Keywords provided by Hospices Civils de Lyon:
Chronic kidney disease
Type 2 diabetes
Randomized trial

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency
Epoetin Alfa
Hematinics processed this record on May 24, 2017